What Can We Expect From Abbott’s Q1’16 Earnings?

+11.85%
Upside
113
Market
127
Trefis
ABT: Abbott Laboratories logo
ABT
Abbott Laboratories

Leading healthcare major, Abbott Laboratories is set to announce its Q1 2016 results on April 20, 2016. A stronger U.S dollar (relative to emerging markets currencies) and a challenging economic environment in Venezuela had together weighed down Abbott’s profitability in Q4’15. We expect the currency effects to continue to impact its profitability throughout 2016. The company’s management had guided a 10% negative impact due to currency effects for 2016 in the previous quarter results. Earlier this quarter, Abbott acquired Alere, a company that should help it gain leadership in point-of-care diagnostics going ahead. Furthermore, we believe that the company’s strong fundamentals will gradually be reflected in its top-line growth when the currency headwinds start to ease. Below we take a look at the key financial metrics as expected for Abbott in Q1’16:

ABT_PREEARN_Q&A_5

See the links below for more information and analysis about Abbott:

Relevant Articles
  1. What’s Next For Abbott Stock After A 6% Rise This Year?
  2. Is Abbott Stock Undervalued At $95?
  3. Which Is A Better Pick – Abbott Stock Or Amgen?
  4. Is Abbott Stock A Better Healthcare Pick Over Thermo Fisher Scientific?
  5. Lower Testing Demand To Weigh On Abbott’s Q2?
  6. Will Abbott Stock Rebound To Its 2022 Highs?

Notes:

1) The purpose of these analyses is to help readers focus on a few important things. We hope such lean communication sparks thinking, and encourages readers to comment and ask questions on the comment section, or email content@trefis.com
2) Figures mentioned are approximate values to help our readers remember the key concepts more intuitively. For precise figures, please refer to our complete analysis for Abbott